Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases

This study has been completed.

First Received on August 30, 2005. Last Updated on November 19, 2009 History of Changes

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00140985

Purpose

Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.

Condition	Intervention	Phase
Renal Disorder	Drug: MK0954, losartan potassium/Duration of Treatment: 20 weeks Drug: Comparator: amlodipine / Duration of Treatment: 20 weeks	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors (TGFß and VEGF)

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure Potassium

Drug Information available for: Amlodipine Amlodipine besylate Losartan Losartan potassium Potassium chloride

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

24h proteinuria

Secondary Outcome Measures:

Changes in the plasma and urinary levels of TGF-beta

Enrollment:	97
Study Start Date:	February 2000
Study Completion Date:	March 2001

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females at least 18 years of age with non-diabetic proteinuric renal diseases

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00140985

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Responsible Party:	Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier:	NCT00140985 History of Changes
Other Study ID Numbers:	2005_058, MK0954-213
Study First Received:	August 30, 2005
Last Updated:	November 19, 2009
Health Authority:	Spain: Ministry of Health

Additional relevant MeSH terms:

Kidney Diseases
Urologic Diseases
Amlodipine
Losartan
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

Cardiovascular Agents
Therapeutic Uses
Vasodilator Agents
Antihypertensive Agents
Anti-Arrhythmia Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists

ClinicalTrials.gov processed this record on February 09, 2012